Portfolio Rapha Capital Management

Poseida Therapeutics: FDA Grants Poseida’s P-BCMA-101 Regenerative Medicine Advanced Therapy (RMAT) Status for Treatment of Multiple Myeloma

By Kevin SlawinNovember 19, 2018February 4th, 2021No Comments

Poseida Therapeutics
FDA Grants Poseida’s P-BCMA-101 Regenerative Medicine Advanced Therapy (RMAT) Status for Treatment of Multiple Myeloma
November 19, 2018

Previous PostBellicum Pharmaceuticals, Inc.: Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant
Next PostAsclepiX Therapeutics Raises $5M in New Funding

© 2024 Ponce Therapeutics. Privacy Policy | Terms & Conditions